Anti-Human CD279 (PD-1) FITC

Grouped product items
Size Price Qty
25 tests
$195.00
100 tests
$440.00

Additional MIH4 Formats

Cat.No. Format Starting From
31811-50 FITC $ 195.00
Catalog Number : 31811-50

description

The MIH4 monoclonal antibody specifically reacts with human Programmed death-1 (PD-1 or CD279), a 50-55 kDA glycoprotein. It is expressed on mainly on activated B, T, and myeloid cells. Within the cytoplasmic region, PD-1 contains an Immunoreceptor tyrosine-based inhibitory motif (ITIM) and seems to regulate peripheral tolerance. The lack or mutation of CD279 is linked to autoimmune disorders.

Additional Information

Clone:
MIH4
Format:
FITC
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest: Adaptive Immunity, Apoptosis
Cell Type: B Cells, T Cells
Application: FC
Clone: MIH4
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Zhang, J. Y., Zhang, Z., Wang, X., Fu, J. L., Yao, J., Jiao, Y., ... & Wang, F. S. (2007). PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood,109(11), 4671-4678.

Bennett, F., Luxenberg, D., Ling, V., Wang, I. M., Marquette, K., Lowe, D., ... & Carreno, B. M. (2003). Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. The Journal of Immunology170(2), 711-718.

Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007). PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clinical Cancer Research13(6), 1757-1761.

© BioGems International, Inc. All rights reserved.